Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s11864-023-01173-1.pdf
Reference64 articles.
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.
2. • Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166. https://doi.org/10.1200/edbk_390166. This manuscript provides a useful overview of the various studies which have influenced treatment practices for mHSPC.
3. Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3): e222246. https://doi.org/10.1001/jamanetworkopen.2022.2246.
4. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7. https://doi.org/10.1038/pcan.2016.30.
5. •• Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747. This is a landmark phase III study that provided level 1 evidence for the combination of docetaxel-based chemotherapy added to androgen deprivation in prostate cancer.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Defining the relationship between clinician-preferred ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer;2024-06-03
2. Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer;Diseases;2024-05-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3